Validation of the agar proportion and 2 liquid systems for testing the susceptibility of Mycobacterium tuberculosis to moxifloxacin

Diagnostic Microbiology and Infectious Disease

Volumn 57, Issue 3, 2007, Pages 283-287

  Piersimoni, Claudio ^a   Lacchini, Carla ^b   Penati, Valeria ^b   Iona, Elisabetta ^c   Fattorini, Lanfranco ^c   Nista, Domenico ^a   Zallocco, Diego ^a   Gesu, Gian Pietro ^b   Codecasa, Luigi ^b  

^a United Hospitals   (Italy)

^b Istituto Villa Marelli   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Critical concentration; Liquid system; Moxifloxacin; Mycobacterium tuberculosis

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; MOXIFLOXACIN; MUTANT PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGAR PROPORTION METHOD; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EXPOSURE; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RADIOMETRY; VALIDATION PROCESS;

AGAR; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES;

EID: 33847265779     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2006.08.018     Document Type: Article

References (25)

1. Baohong J.I., Lounis N., Maslo C., Trouffot-Pernot C., Bonnafous P., and Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42 (1998) 2066-2069
2. Bozeman L., Burman W., Metchock B., Welch L., Weiner M., and and the Tuberculosis Trial Consortium. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Europe. Clin. Infect. Dis. 40 (2005) 386-391
3. Burman W.J., Goldberg S., Johnson J.L., Muzanye G., Engle M., Mosher A.W., Choudhri S., Daley C.L., Munsiff S.S., Zhao Z., Vernon A., Chaisson R., and and the Tuberculosis Trial Consortium. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174 (2006) 331-338
4. Codecasa L.R., Ferrara G., Ferrarese M., Morandi M.A., Penati V., Lacchini C., Vaccarino P., and Migliori G.B. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir. Med. 100 (2006) 1566-1572
5. Fattorini L., Iona E., Ricci M.L., Thoresen O.F., Orrù G., Oggioni M.R., Tortoli E., Piersimoni C., Chiaradonna P., Tronci M., Pozzi G., and Orefici G. Activity of 16 antimicrobial agents against drug-resistant of Mycobacterium tuberculosis. Microb. Drug Resist. 5 (1999) 265-270
6. Giannoni F., Iona E., Sementilli F., Brunori L., Pardini M., Migliori G.B., Orefici G., and Fattorini L. Evaluation of new line probe assay for rapid identification of gyr A mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49 (2005) 2928-2933
7. Gillespie H.S., and Billington O. Activity of moxifloxacin against mycobacteria. J. Antimicrob. Chemother. 44 (1999) 393-395
8. Ginsburg A.S., Hooper N., Parrish N., Dooley K.E., Dorman S.E., Booth J., Diener-West M., Merz W.G., Bishai W.R., and Sterling T. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin. Infect. Dis. 37 (2003) 1448-1452
9. Gosling R.D., Uliso L.O., Sam N.E., Bongard E., Kanduma E.G., Nyindo M., Morris R.W., and Gillespie S.H. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 168 (2003) 1342-1345
10. Heifets L.B. Drug susceptibility tests in the management of chemotherapy of tuberculosis. In: Hiefets L.B. (Ed). Drug susceptibility in the chemotherapy of mycobacterial infections (1991), CRC Press, Inc, Boca Raton, FL 89-121
11. Hu Y., Coates A.R.M., and Mitchison D. Sterilizing activity of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47 (2003) 653-657
12. Krüüner A., Yates M.D., and Drobniewsky F.A. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first and second-line antimicrobial drugs with drug resistant clinical strains of Mycobacterium tuberculosis. J. Clin. Microbiol. 44 (2006) 811-818
13. National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardia and Other Aerobic Actinomycetes. Approved Standard M24-A (2003), National Committee for Clinical Laboratory Standards, Wayne, PA
14. O'Brien R. Development of fluoroquinolones as first-line drugs for tuberculosis-at long last!. Am. J. Respir. Crit. Care Med. 168 (2003) 1266-1267
15. Pfyffer G.E., Bonato D.A., Ebrahimzadeh A., Gross W., Hotaling J., Kornblum J., Laszlo A., Roberts G., Salfinger M., Wittwer F., and Siddiqi S. Multicenter laboratory validation of susceptibility testing against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J. Clin. Microbiol. 37 (1999) 3179-3186
16. Pletz M.W.R., De Roux A., Roth A., Neumann K.H., Mauch H., and Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective randomized study. Antimicrob. Agents Chemother. 48 (2004) 780-782
17. Richeldi L., Corvi M., Ferrara G., Franco F., Vailati P., Meschiari F., et al. Clinical use of levofloxacin in the long-term treatment of drug resistant tuberculosis. Monaldi Arch. Chest Dis. 57 (2002) 39-43
18. Rodriguez J.C., Ruiz M., Lopez M., and Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20 (2002) 464-467
19. Sanders C.A., Nieda R.R., and Desmond E.P. Validation of the use of 7H10 agar, BACTEC MGIT 960 and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin. J. Clin. Microbiol. 42 (2004) 5225-5228
20. Siddiqi S. BACTEC 460 TB (Radiometric) System. Indirect susceptibility testing for Mycobacterium tuberculosis. In: Isemberg H.D. (Ed). Clinical microbiology procedures handbook (2004), American Society for Microbiology, Washington, DC 7.8.1.1
21. Siddiqi S. BACTEC MGIT 960 SIRE. Nonradiometric susceptibility testing for Mycobacterium tuberculosis. In: Isemberg H.D. (Ed). Clinical microbiology procedures handbook (2004), American Society for Microbiology, Washington, DC 7.8.5.1
22. Sullivan J.T., Woodruff M., Lettieri J., Agarwal V., Krol G.J., Leese P.T., Watson S., and Heller A.H. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolones. Antimicrob. Agents Chemother. 43 (1999) 2793-2797
23. Veziris N., Trouffot-Pernot C., Aubry A., Jarlier V., and Lounis N. Fluoroquinolone-containing third line regimen against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 47 (2003) 3117-3122
24. Yoon G.S., Lee H.J., Yoon H.I., Kim Y.W., Han S.K., Shim Y.S., and Yim J.J. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. Int. J. Tuberc. Lung Dis. 9 (2005) 1215-1219
25. Xu C., Kreswirth B.N., Sreevatsan S., Musser J.M., and Drlica K. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J. Infect. Dis. 174 (1996) 1127-1130